Clinical Data Published in Vaccine Demonstrate Robust Immune Response With Agenus (Formerly known as Antigenics Inc. - Lexington, MA)’ Herpes Vaccine Containing QS-21 Adjuvant

LEXINGTON, Mass., Sept. 26, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced positive results from a randomized, four-arm Phase 1 study of HerpV, a recombinant (off-the-shelf) therapeutic vaccine for the treatment of genital herpes, which included the Company’s proprietary QS-21 Stimulon® adjuvant. The results were published in the peer-reviewed journal Vaccine.